Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer | NEJM
ASCO 2019: ARCHES: Efficacy of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-sensitive Prostate Cancer
mCSPC: ARCHES Trial | XTANDI® (enzalutamide) | HCP Site
Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADT
ASCO GU 2022: Overall Survival in Patients with mHSPC Treated with Enzalutamide + ADT by High or Low Disease Volume and Progression to mHSPC (M0 at Diagnosis) or de novo mHSPC (M1
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol - The
AUA 2022: Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3
ASCO GU 2022: Overall Survival in Patients with mHSPC Treated with Enzalutamide + ADT by High or Low Disease Volume and Progression to mHSPC (M0 at Diagnosis) or de novo mHSPC (M1
ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses | Journal of Urology
AUA 2022 Annual Meeting
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses | Journal of Urology
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses | Journal of Urology
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study - ScienceDirect
ESMO 2021: Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men With mHSPC
Cancer Trial Results
ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis - ScienceDirect
mCSPC: ARCHES Trial | XTANDI® (enzalutamide) | HCP Site
mCSPC: ARCHES Trial | XTANDI® (enzalutamide) | HCP Site
Cancer Trial Results
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study - ScienceDirect
PDF) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Frontiers | Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
